PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Miguel A EscobarJames LuckYevhenii AverianovJonathan DucoreMaria Fernanda López FernándezAdam GiermaszDaniel P HartJanna JourneycakeCraig M KesslerCindy LeissingerJohnny N MahlanguLaura Villarreal MartinezWolfgang MiesbachIsmail Haroon MithaDoris QuonMark T RedingJean-François SchvedOleksandra StasyshynKateryna V VilchevskaMichael WangJerzy WindygaW Allan AlexanderAhmad Al-SabbaghDaniel BonzoIan S MitchellThomas A WilkinsonCédric HermansPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)
Two eptacog beta dosing regimens in PwHABI undergoing major and minor surgical procedures were well-tolerated, and the majority of procedures were successful based on surgeon/investigator assessments. Eptacog beta offers clinicians a new potential therapeutic option for procedures in PwHABI.